Alert to US Physicians: DHEA, Widely Used as an OTC Androgen Supplement, May Exacerbate COVID-19

    December 2020 in “ Endocrine-related Cancer
    Jonathan W. Nyce
    Image of study
    TLDR The over-the-counter supplement DHEA could make COVID-19 worse, especially in diabetics and people with G6PD deficiency.
    The document discusses the potential risks of DHEA (Dehydroepiandrosterone), an over-the-counter androgen supplement widely used in the US, in exacerbating COVID-19. DHEA induces the ACE-2 receptor and TMPRS22, key to the virus's entry and infection process, and inhibits glucose-6-phosphate dehydrogenase (G6PD), making G6PD-deficient cells more susceptible to coronavirus infection. The document suggests that DHEA may contribute to SARS-CoV-2-induced vascular endothelialitis, leading to multi-organ inflammatory reactions, especially in diabetic patients and those with G6PD deficiency. The authors recommend considering the suspension of over-the-counter availability of DHEA unless its safety can be proven in placebo-controlled, randomized, double-blind clinical trials.
    Discuss this study in the Community →

    Related Community Posts Join

    6 / 97 results

    Similar Research

    5 / 1000+ results
      Roles of Steroid Receptors in the Lung and COVID-19

      research Roles of Steroid Receptors in the Lung and COVID-19

      9 citations , July 2021 in “Essays in Biochemistry”
      Sex hormones may influence COVID-19 severity, with males at higher risk, and certain hormone therapies could potentially treat the virus.
      Male Sex Hormones, Aging, And Inflammation

      research Male Sex Hormones, Aging, And Inflammation

      60 citations , January 2023 in “Biogerontology”
      Adequate testosterone is crucial for men's health and quality of life, but its decline with age needs more research.
      COVID-19 and Hypopituitarism

      research COVID-19 and Hypopituitarism

      15 citations , August 2021 in “Reviews in endocrine and metabolic disorders”
      COVID-19 and hypopituitarism (reduced pituitary gland function) are linked, with the latter's related health issues potentially worsening COVID-19 outcomes, and COVID-19 possibly increasing risk for pituitary complications.